DBV Technologies Stock Rebounds Over 3%, Among Top Gainers in SBF 120
The French biotech company regains momentum in mid-morning trading, bucking the trend of a declining SBF 120. The stock is among the top gainers of the broad index, after a sharp decline in the previous session. However, declared short positions remain at a high level.
Stock Moves Above Its 20-Day Moving Average but Stays Below Medium-Term Averages
DBV Technologies' stock is up 3.19% at €2.91 in mid-morning trading, among the strongest gains in the SBF 120 as the index drops by 0.26%. The stock recovers some of the 5% loss from the previous day and moves above its 20-day moving average of €2.88. However, the rebound is still limited in the context of recent weeks, with a decline of 13.4% over one month and 19.7% over three months. The technical setup remains fragile. The 50-day and 200-day moving averages at €3.17 and €3.09, respectively, stay above the current price, with gaps of 8.2% and 5.8%. The RSI at 42 indicates a still neutral momentum, with no sign of seller exhaustion. Over twelve months, the performance remains positive at over 82%, highlighting the extent of the consolidation since the highs in spring.
A Cumulative Short of 3.45% of Capital, Increasing Over the Month
According to reviewed declarations, three funds have a combined 3.45% of the capital sold short, up from 2.80% a month earlier, marking a 0.65 percentage point increase. This dynamic reflects a strengthening bearish pressure over thirty days, though not yet massive relative to the float. It is a point to monitor, but not a unique signal for reversal. This pressure contrasts with recent operational news. A few days ago, the biotech confirmed its intention to submit its application to the FDA for the Viaskin Peanut patch in the third quarter of 2026, following finalized discussions with the American agency. The next technical milestone remains the resistance at €3.36, aligned with the 50-day moving average of €3.17. The consensus among analysts is worth monitoring as the expected regulatory submission approaches.
